Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.72 -0.16 (-1.01%)

Streaming Delayed Price Updated: 12:23 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Volume	353,742
Open	15.67
Bid (Size)	15.70 (200)
Ask (Size)	15.73 (100)
Prev. Close	15.88
Today's Range	15.39 - 15.77
52wk Range	13.83 - 36.91
Shares Outstanding	97,381,774
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

February 17, 2026

From Summit Therapeutics

Via Business Wire

One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens ↗

February 03, 2026

The iShares Ethereum Trust ETF provides regulated exposure to ether’s price performance for institutional and retail investors alike.

Via The Motley Fool

Performance

YTD	-10.3%	-10.3%
1 Month	-2.1%	-2.1%
3 Month	-5.1%	-5.1%
6 Month	-39.2%	-39.2%
1 Year	-25.4%	-25.4%

More News

Is SharpLink Gaming Stock a Buy or Sell After Apeiron Capital Sold Its Stake Valued at $23 Million? ↗

February 02, 2026

Via The Motley Fool

2 Stocks That Could Soar This Year ↗

January 31, 2026

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 30, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

January 29, 2026

From Summit Therapeutics

Via Business Wire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Via MarketMinute

2 Biotech Stocks That Could Soar This Year ↗

January 12, 2026

Via The Motley Fool

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

January 12, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

January 12, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Summit Therapeutics

Via Business Wire

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗

January 06, 2026

Via The Motley Fool

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Summit Therapeutics

Via Business Wire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

Via MarketMinute

Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗

December 10, 2025

Via The Motley Fool

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗

December 09, 2025

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Summit Therapeutics

Via Business Wire

Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗

December 05, 2025

Via The Motley Fool

Don't Buy Summit Therapeutics Until This Big Thing Happen ↗

December 03, 2025

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 02, 2025

Via The Motley Fool

Summit SMMT Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

November 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Present at Upcoming Investor Conferences

November 04, 2025

From Summit Therapeutics

Via Business Wire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

October 31, 2025

From Summit Therapeutics

Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?

Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Summit Therapeutics Inc. - Common Stock trade on?

Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?

The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market

What is the current price of Summit Therapeutics Inc. - Common Stock?

The current price of Summit Therapeutics Inc. - Common Stock is 15.72

When was Summit Therapeutics Inc. - Common Stock last traded?

The last trade of Summit Therapeutics Inc. - Common Stock was at 02/19/26 12:23 PM ET

What is the market capitalization of Summit Therapeutics Inc. - Common Stock?

The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.53B

How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?

Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.